7 Myths About Prostate Cancer Debunked
Despite how common prostate cancer is in American men, misconceptions about its symptoms, detection, treatment, and management persist.
Despite how common prostate cancer is in American men, misconceptions about its symptoms, detection, treatment, and management persist.
A single-institution study found no significant increase in the risk for complications or readmissions between patients who underwent robotic urologic surgery before and during the COVID-19 pandemic.
Surgical and nonsurgical local salvage treatments for prostate cancer (PCa) that recurs following radiation therapy offer similar 5-year recurrence-free survival (RFS) rates, but re-irradiation appears to result in less toxicity, according to a new meta-analysis. A team led by Amar U. Kishan, MD, of the University of California, Los Angeles, analyzed data from 150 studies…
Delaying radical prostatectomy for high-risk clinically localized prostate cancer for up to 6 months does not increase the risk for adverse pathologic outcomes, a study found.
By 2016, radical prostatectomy use nearly equaled radiation therapy use for high-risk prostate cancer.
Deferring radical prostatectomy for intermediate- and high-risk prostate cancer for several months does not increase the risk for adverse oncologic findings.
Given that the findings do not show major differences between care options in prostate cancer, cost probably shouldn’t be a major factor driving decision making.
Patients with localized prostate cancer characterized by high-risk features are at increased risk of a negative outcome following radical prostatectomy.
Combining sipuleucel-T and radium-223 improves progression-free survival among men with metastatic castration-resistant prostate cancer (mCRPC) who have bone predominant metastases, a randomized phase 2 study found.
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.